Long COVIDNCT05705648
Nutritional Management of Post COVID-19 Cognitive Symptoms
A study testing medium chain triglyceride oil and Safflower oil in people with Long COVID, run by University of Alberta at 1 site in Canada.
Trial summary
The goal of this clinical trial is to learn about in brain "fog" complaints associated with long-COVID in people aged 22-50-years. The main questions it aims to answer are: the natural course of brain "fog" complaints the effect, if any of supplemental dietary oil on brain "fog" complaints Participants will be asked… Read more about this study
- Who is it for?
- Ages 22 to 50 years
- Conditions the study is for
- Long COVID
- What is being tested?
- medium chain triglyceride oil and Safflower oil
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 103 participants
- Where
- 1 siteCanada
- Study dates
- 1 Oct 2023to 1 Mar 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 to 50 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- confirmed COVID infection, at least 3 months previously, with ongoing cognitive complaints
- all other medical conditions stable, and on stable doses of medications (if required)
Who cannot join
- COVID infection not confirmed by PCR or Rapid test
- unable to speak English
- pre-COVID cognitve complaints, and/or medical diagnoses affecting cognitive function
Trial locations and contacts
1 site in 1 country.
About this study
The goal of this clinical trial is to learn about in brain "fog" complaints associated with long-COVID in people aged 22-50-years. The main questions it aims to answer are:
- the natural course of brain "fog" complaints
- the effect, if any of supplemental dietary oil on brain "fog" complaints Participants will be asked to undergo some brain testing (X-rays and questions. Treatments they'll be given will be one of two supplemental oils to consume daily.
Researchers will compare outcomes in the two different oil groups to see if it has any effect on brain "fog" complaints.
Read the detailed description
Randomized placebo-control clinical trial comparing two types of nutritional oil and evaluating the impact, if any, on subjective complaints of long-COVID cognitive changes.
- Conditions
- Long COVID
- Being tested
- medium chain triglyceride oil, Safflower oil
- Keywords
- brain fog; confusion; memory loss; functional decline
- Medical subject headings
- Post-Acute COVID-19 Syndrome, Mental Fatigue, Confusion, Memory Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
medium chain triglyceride oilDietary supplement
Medium chain triglyceride oil
Safflower oilDietary supplement
Safflower oil
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | Medium chain triglyceride oil 15ml tid x 5 months Receives: Dietary Supplement: medium chain triglyceride oil |
| Placebo | Placebo comparator | Safflower oil 15mls tid x 5 months Receives: Dietary Supplement: Safflower oil |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cognigram(R)
computer-based cognitive test
Measured: 12-months
Secondary outcomes (1)
Montreal Cognitive Assessment
Cognitive test
Measured: 12-months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jan 2023
- Study start1 Oct 2023
- Primary completion24 Jun 2026
- Study completion1 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Long COVIDStudies of the same condition, open and under way.
- More trials run by University of AlbertaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomised placebo-controlled clinical trial
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 103 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Alberta
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05705648
- Sponsor's protocol ID
- Pro00109795
- Status last verified
- Jul 2026
- First submitted
- 27 Jan 2023
- Last updated
- 17 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Nutritional Management of Post COVID-19 Cognitive Symptoms
- ClinicalTrials.gov ID
- NCT05705648
- Acronym / sponsor ID
- Pro00109795
- Conditions
- Long COVID
- Keywords
- brain fog; confusion; memory loss; functional decline
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 103 participants (actual)
- Lead sponsor
- University of AlbertaUniversity, hospital or other
- Study start
- 1 Oct 2023 (actual)
- Primary completion
- 24 Jun 2026 (actual)
- Study completion
- 1 Mar 2027 (estimated)
- First posted
- 31 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn about in brain "fog" complaints associated with long-COVID in people aged 22-50-years. The main questions it aims to answer are:
- the natural course of brain "fog" complaints
- the effect, if any of supplemental dietary oil on brain "fog" complaints Participants will be asked to undergo some brain testing (X-rays and questions. Treatments they'll be given will be one of two supplemental oils to consume daily.
Researchers will compare outcomes in the two different oil groups to see if it has any effect on brain "fog" complaints.
Detailed description
Randomized placebo-control clinical trial comparing two types of nutritional oil and evaluating the impact, if any, on subjective complaints of long-COVID cognitive changes.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Randomised placebo-controlled clinical trial
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Dietary Supplement: medium chain triglyceride oilMedium chain triglyceride oil 15ml tid x 5 months |
| Placebo | Placebo comparator | Dietary Supplement: Safflower oilSafflower oil 15mls tid x 5 months |
Who may qualify
- Ages
- 22 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- confirmed COVID infection, at least 3 months previously, with ongoing cognitive complaints
- all other medical conditions stable, and on stable doses of medications (if required)
Key exclusion criteria (3 listed)
- COVID infection not confirmed by PCR or Rapid test
- unable to speak English
- pre-COVID cognitve complaints, and/or medical diagnoses affecting cognitive function
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| medium chain triglyceride oilMedium chain triglyceride oil | Dietary supplement | Intervention |
| Safflower oilSafflower oil | Dietary supplement | Placebo |
Primary outcome
Cognigram(R)
Time frame: 12-months
computer-based cognitive test
1 secondary outcome
Montreal Cognitive Assessment
Time frame: 12-months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Long COVID
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)
Not yet recruitingPhase 3
The Study of Brave-LC LDN Treatment Trial
Post-acute COVID-19 Syndrome
Active, not recruitingObservational study
Epigenetic Changes in Long COVID Patients
Long COVID-19 Syndrome, Long COVID Symptoms
Enrolling by invitationPhase 2
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
Systemic Inflammation, Neuroinflammation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing medium chain triglyceride oil and Safflower oil in people with Long COVID, run by University of Alberta at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 17 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cognigram(R) (time frame: 12-months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2026.